Endothelial Dysfunction and Vascular Disease
The vascular endothelium (single-cell monolayer; ~6×1013 cells; ~700m2 surface area) regulates vasomotor tone, leucocyte trafficking, haemostasis, and vascular permeability. Endothelial dysfunction (ED) — characterised by reduced NO bioavailability, ICAM-1/VCAM-1 upregulation, and eNOS uncoupling — is the earliest atherosclerotic event, preceding plaque formation by decades. Pathophysiology: ROS superoxide quenches NO (forming peroxynitrite, ONOO−), reducing vasodilation and enabling leucocyte adhesion. Oxidised LDL activates LOX-1 receptors, triggering endothelial apoptosis and NF-κB-driven adhesion molecule expression. Insulin resistance reduces PI3K→Akt→eNOS phosphorylation, further impairing NO production. ED predicts cardiovascular event risk independently of classical risk factors.
Spirulina Mechanisms in Endothelial Function
eNOS Activation and NO Bioavailability Enhancement
Spirulina polyphenols and AMPK activation phosphorylate eNOS at Ser1177 via PI3K→Akt→eNOS cascade, increasing NO production (+20–35% L-arginine→NO conversion efficiency). eNOS Ser1177 phosphorylation also enhances eNOS coupling (prevents uncoupled superoxide generation from tetrahydrobiopterin-deficient eNOS). Polyphenol ROS scavenging reduces superoxide competing with NO, further increasing NO bioavailability (+15–25% NOx in endothelial cells under oxidative conditions). Increased NO activates sGC→cGMP→PKG in vascular smooth muscle, causing vasodilation and reducing systolic BP by 4–8 mmHg in hypertensive subjects.
ICAM-1/VCAM-1 Downregulation and Leucocyte Adhesion Prevention
Spirulina phycocyanin inhibits NF-κB p65 nuclear translocation in endothelial cells challenged with TNF-α or LPS, reducing transcription of adhesion molecules: ICAM-1 (−25–40%), VCAM-1 (−20–35%), E-selectin (−20–30%). Reduced adhesion molecule expression prevents monocyte rolling, firm adhesion, and transmigration into subintimal space, blocking the initial step of atherosclerotic plaque formation. This mechanism is distinct from and additive to statins (which reduce LDL without direct endothelial NF-κB inhibition).
oxLDL Reduction and Foam Cell Prevention
Spirulina carotenoids reduce plasma oxidised LDL (oxLDL/MDA-LDL) by 15–25%, lowering LOX-1 receptor activation on endothelial cells. Reduced LOX-1 signalling decreases endothelial ROS production (LOX-1→NADPH oxidase feedback), apoptosis (LOX-1→caspase-3), and ICAM-1 expression, creating a protective anti-atherosclerotic circuit. In macrophages, reduced oxLDL decreases SR-A (scavenger receptor A) foam cell formation (−20–30% cholesterol ester accumulation), directly limiting plaque lipid core expansion.
eNOS Coupling and Tetrahydrobiopterin Preservation
eNOS uncoupling occurs when tetrahydrobiopterin (BH4) is oxidised by peroxynitrite, causing eNOS to generate superoxide instead of NO, amplifying oxidative damage. Spirulina Nrf2-driven antioxidant upregulation preserves BH4 from oxidation (−20–30% BH4 oxidation to BH2 in ROS-challenged endothelium), maintaining eNOS coupling. GTP cyclohydrolase I (GTPCH-I, rate-limiting BH4 biosynthesis enzyme) expression increases +15–20% via Nrf2-mediated upregulation, increasing BH4 synthesis. Coupled eNOS produces 3–5× more NO per unit L-arginine than uncoupled eNOS.
Clinical Cardiovascular Outcomes
- FMD (flow-mediated dilation): +1.5–3% absolute improvement at 12 weeks
- Systolic BP: −4–8 mmHg in hypertensive subjects
- Diastolic BP: −2–5 mmHg
- oxLDL: −15–25%
- Serum ICAM-1 (soluble): −20–30%
- Arterial stiffness (PWV): −0.5–1.2 m/s at 16 weeks
Dosing and Drug Interactions
Endothelial dysfunction/hypertension: 5–10g daily for 12–16 weeks. Statins: Additive; statin LDL reduction + spirulina endothelial NO/NF-κB effects complement each other. ACE inhibitors/ARBs: Additive BP reduction; monitor for hypotension. PDE5 inhibitors: Mechanistically compatible (both increase NO/cGMP pathway). Aspirin: Complementary; spirulina does not affect platelet COX-1. Summary: eNOS +20–35% NO, ICAM-1/VCAM-1 −25–40%, oxLDL −15–25%, BH4 preservation; dosing 5–10g for 12–16 weeks. NK concern: low.